This HTML5 document contains 107 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/chebi/
n30http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/wikipedia/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/bindingdb/
n5http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n7http://www.rxlist.com/cgi/generic/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/pubchem-substance/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/drugbank/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/national-drug-code-directory/
n16http://www.drugs.com/cdi/
n11http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00593/identifier/chemspider/
n22http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00593
rdf:type
n3:Drug
n3:description
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [PubChem]
n3:dosage
n19:271B5223-363D-11E5-9242-09173F13E4C5 n19:271B5224-363D-11E5-9242-09173F13E4C5 n19:271B5222-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Patsalos PN: Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:140-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16302888 # Coulter DA, Huguenard JR, Prince DA: Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett. 1989 Mar 13;98(1):74-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2710401 # Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2545161 # Coulter DA, Huguenard JR, Prince DA: Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol. 1990 Aug;100(4):800-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2169941 # Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN: Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons. Neuroscience. 1992 Dec;51(4):755-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1336826
n3:group
approved
n3:halfLife
53 hours
n3:indication
For the treatment of petit mal epilepsy.
n3:manufacturer
n15:271B5219-363D-11E5-9242-09173F13E4C5 n15:271B521A-363D-11E5-9242-09173F13E4C5 n15:271B5217-363D-11E5-9242-09173F13E4C5 n15:271B5218-363D-11E5-9242-09173F13E4C5 n15:271B5216-363D-11E5-9242-09173F13E4C5 n15:271B521B-363D-11E5-9242-09173F13E4C5 n15:271B521C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n5:DB00593 n12:DB00593
dcterms:title
Ethosuximide
adms:identifier
n10:46507617 n17:50240424 n18:4887 n20:Ethosuximide n23:PA449533 n24:3291 n25:D00539 n26:0071-0237-24 n27:C07505 n28:3175 n29:DB00593
n3:mechanismOfAction
Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.
n3:packager
n15:271B520F-363D-11E5-9242-09173F13E4C5 n15:271B5210-363D-11E5-9242-09173F13E4C5 n15:271B520D-363D-11E5-9242-09173F13E4C5 n15:271B520E-363D-11E5-9242-09173F13E4C5 n15:271B5213-363D-11E5-9242-09173F13E4C5 n15:271B5214-363D-11E5-9242-09173F13E4C5 n15:271B5211-363D-11E5-9242-09173F13E4C5 n15:271B5212-363D-11E5-9242-09173F13E4C5 n15:271B5215-363D-11E5-9242-09173F13E4C5
n3:synonym
alpha-Ethyl-alpha-methylsuccinimide 3-Methyl-3-ethylsuccinimide Etosuximida 3-ethyl-3-methyl-2,5-pyrrolidinedione 3-Methyl-3-ethylpyrrolidine-2,5-dione Ethosuximide Ethosuximid Aethosuximide Atysmal (+-)-2-Ethyl-2-methylsuccinimide alpha-Methyl-alpha-ethylsuccinimide (±)-2-ethyl-2-methylsuccinimide Ethosuximidum 3-Ethyl-3-methylsuccinimide gamma-Ethyl-gamma-methyl-succinimide γ-ethyl-γ-methyl-succinimide 2-Methyl-2-ethylsuccinimide gamma-Methyl-gamma-ethyl-succinimide 2-ethyl-2-methylsuccinimide Thilopemal
n3:toxicity
Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.
n21:hasAHFSCode
n30:28-12-20
n3:foodInteraction
Avoid alcohol. Take with food.
n3:synthesisReference
Miller, C.A. and Long, L.M.; U.S. Patent 2,993,835; July 25,1961; assigned to Parke, Davis and Company.
n13:hasConcept
n14:M0007887
foaf:page
n7:ethosuximide.htm n16:ethosuximide.html
n3:IUPAC-Name
n11:271B5229-363D-11E5-9242-09173F13E4C5
n3:InChI
n11:271B522F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n11:271B522E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B522B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n11:271B522C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n11:271B522D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B523F-363D-11E5-9242-09173F13E4C5 n11:271B5227-363D-11E5-9242-09173F13E4C5
n3:logP
n11:271B5241-363D-11E5-9242-09173F13E4C5 n11:271B5225-363D-11E5-9242-09173F13E4C5 n11:271B5228-363D-11E5-9242-09173F13E4C5
n3:logS
n11:271B5226-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n22:N03AD01
n3:H-Bond-Acceptor-Count
n11:271B5235-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n11:271B5236-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n11:271B5230-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n11:271B5231-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n11:271B5233-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n11:271B5232-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n11:271B5234-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability following oral administration is 93%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
77-67-8
n3:category
n3:containedIn
n8:271B521F-363D-11E5-9242-09173F13E4C5 n8:271B5220-363D-11E5-9242-09173F13E4C5 n8:271B521D-363D-11E5-9242-09173F13E4C5 n8:271B521E-363D-11E5-9242-09173F13E4C5 n8:271B5221-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n11:271B523B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n11:271B523D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n11:271B523E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n11:271B5240-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n11:271B523A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n11:271B5239-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n11:271B523C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n11:271B522A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n11:271B5237-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n11:271B5238-363D-11E5-9242-09173F13E4C5